Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 juin 2015 08h00 HE | Source: Cellerant Therapeutics

Cellerant Appoints Rodney Young as Chief Financial Officer

SAN CARLOS, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...
17 mars 2015 08h00 HE | Source: Cellerant Therapeutics

Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients

SAN CARLOS, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...
05 déc. 2014 13h07 HE | Source: Cellerant Therapeutics

Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients With Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting

SAN CARLOS, Calif., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., announced that data from the Phase 1 clinical trial for CLT-008, a first-in-class, allogeneic, cell-based therapy for...
11 sept. 2014 08h00 HE | Source: Cellerant Therapeutics

Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008

Total Contract With Biomedical Advanced Research and Development Authority Valued at $163.8MM Additional Funding to Support Planned Phase 2 Trial With CLT-008 in AML SAN CARLOS, Calif., Sept....